The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis

The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis

Abstract Background Major depressive disorder causes a great burden on patients and societies. Venlafaxine and mirtazapine are commonly prescribed as second-line treatment for patients with major depressive disorder worldwide. Previous systematic reviews have concluded that venlafaxine and mirtazapi...

Full description

Bibliographic Details
Main Authors: Caroline Kamp Jørgensen, Sophie Juul, Faiza Siddiqui, Mark Abie Horowitz, Joanna Moncrieff, Klaus Munkholm, Michael Pascal Hengartner, Irving Kirsch, Christian Gluud, Janus Christian Jakobsen
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Systematic Reviews
Subjects:
Antidepressants
Venlafaxine
Mirtazapine
Major depressive disorder
Beneficial effects
Adverse events
Online Access:https://doi.org/10.1186/s13643-023-02221-5

Internet

https://doi.org/10.1186/s13643-023-02221-5

Similar Items